Myelofibrosis
Ojjaara Approved for Myelofibrosis Patients With Anemia
The FDA approved momelotinib (Ojjaara, GSK) for the treatment of intermediate- or high-risk myelofibrosis, ...
SEPTEMBER 20, 2023
Data Show Momelotinib’s Value in Patients With Myelofibrosis and Anemia
New findings published in the Lancet (2023;401:269-280) suggest momelotinib (GSK) can be a valuable addition to the ...
MARCH 3, 2023
Phase 3 Study Shows Benefit of JAK Inhibitor in Symptomatic Myelofibrosis
For previously treated myelofibrosis, the novel JAK inhibitor momelotinib (GlaxoSmithKline) appears to offer a ...
JULY 8, 2022
FDA Approves Inrebic to Treat Myelofibrosis
The orphan drug fedratinib is the second FDA-approved medication to myelofibrosis.
AUGUST 20, 2019
Pacritinib Trials in MF to Continue
For those receiving blood transfusions at baseline, there was a reduction in transfusion dependence from baseline ...
APRIL 10, 2017
Expert Advice: Srdan Verstovsek, MD, PhD, On the Essential Oncology App
During the 2015 ASH Annual Meeting, we sat down with Srdan Verstovsek, MD, PhD, to chat about the Essential ...
FEBRUARY 19, 2016
